Patents by Inventor Diana Shpektor

Diana Shpektor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody molecules having specificity for human OX40
    Patent number: 10017575
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 10, 2018
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody molecules having specificity for human OX40
    Publication number: 20160355598
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody molecules having specificity for human OX40
    Patent number: 9428570
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: August 30, 2016
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody molecules having specificity for human OX40
    Patent number: 8614295
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 24, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20130330344
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 12, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20100254978
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: February 17, 2010
    Publication date: October 7, 2010
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Ligands for TGF-beta binding proteins and uses thereof
    Patent number: 7226902
    Abstract: Compositions and methods are provided that relate to the unexpected specific association of (i) the TGF-beta binding protein sclerostin with the BMP antagonist protein chordin to form a complex, and of (ii) the TGF-beta binding protein sclerostin with the BMP antagonist protein noggin to form a complex, either of which complex is incapable of binding to a TGF-beta superfamily member such as a BMP. The invention provides isolated complexes for use in screening assays to identify agents that modulate bone mineralization, and offers other related advantages.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: June 5, 2007
    Assignee: Celltech R&D, Inc.
    Inventors: David G. Winkler, John Latham, John Skonier, Diana Shpektor, Trenton Hayes, James Geoghegan
  • Ligands for TGF-beta binding proteins and uses thereof
    Publication number: 20050085418
    Abstract: Compositions and methods are provided that relate to the unexpected specific association of (i) the TGF-beta binding protein sclerostin with the BMP antagonist protein chordin to form a complex, and of (ii) the TGF-beta binding protein sclerostin with the BMP antagonist protein noggin to form a complex, either of which complex is incapable of binding to a TGF-beta superfamily member such as a BMP. The invention provides isolated complexes for use in screening assays to identify agents that modulate bone mineralization, and offers other related advantages.
    Type: Application
    Filed: March 12, 2004
    Publication date: April 21, 2005
    Applicant: CELLTECH R & D LTD.
    Inventors: David Winkler, John Latham, John Skonier, Diana Shpektor, Trenton Hayes, James Geoghegan